Depemokimab, an ultra-long-acting biologic agent with enhanced binding affinity for interleukin-5, may improve outcomes in patients with asthma with an eosinophilic phenotype. New research ...

During the years 1932 to 1945, post-mortem examination disclosed 26 cases of this lesion at the Mallory Institute of Pathology, Boston City Hospital, and at the Peter Bent Brigham Hospital, 19 of ...

From August 8, 2018, to January 14, 2020, we vaccinated 265,183 participants. Of these vaccinees, 102,515 were monitored on days 0, 3, and 21 for safety. Among the contacts and contacts-of ...

Prevention of drug-resistant tuberculosis is a global health priority. However, trials evaluating the effectiveness of treating Mycobacterium tuberculosis infection among contacts of persons with ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

Worldwide, approximately 2 million children younger than 15 years of age are infected with multidrug-resistant (MDR) Mycobacterium tuberculosis, with MDR tuberculosis developing in approximately ...

Dr. James Q. Zhou (Medicine): A 56-year-old woman with metabolic dysfunction–associated steatohepatitis and cirrhosis was admitted to this hospital because of end-stage liver disease. The ...

Trials evaluating the effectiveness of treating Mycobacterium tuberculosis infection among contacts of persons with drug-resistant tuberculosis are lacking. New research findings are summarized in ...

AN iron-deficiency anemia associated with chronic dysphagia and glossitis in women between forty and fifty years of age is now known as side-ropenic dysphagia. Historically, the entity has borne ...

Whether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear. In this prospective, randomized, noninferiority trial, we ...

Daily insulin injections can be a burden for patients with type 2 diabetes. Insulin efsitora is a new basal insulin that can be given once weekly. New research findings comparing efsitora with ...